Associated Papers
Imaging NRF2 activation in non-small cell lung cancer with positron emission tomography.
Greenwood HE et al.
Nature Communications, 2024
PPIA dictates NRF2 stability to promote lung cancer progression.
Lu W et al.
Nature Communications, 2024
Imaging the master regulator of the antioxidant response in non-small cell lung cancer with positron emission tomography.
Greenwood HE et al.
Biorxiv : the Preprint Server for Biology, 2023
A NRF2 inhibitor selectively sensitizes KEAP1 mutant tumor cells to cisplatin and gefitinib by restoring NRF2-inhibitory function of KEAP1 mutants.
Aboulkassim T et al.
Cell Reports, 2023
Targeting NFE2L2/KEAP1 Mutations in Advanced NSCLC With the TORC1/2 Inhibitor TAK-228.
Paik PK et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2023
Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer.
Bartolacci C et al.
Nature Communications, 2022
A targetable CoQ-FSP1 axis drives ferroptosis- and radiation-resistance in KEAP1 inactive lung cancers.
Koppula P et al.
Nature Communications, 2022
The acylfulvene alkylating agent, LP-184, retains nanomolar potency in non-small cell lung cancer carrying otherwise therapy-refractory mutations.
Kulkarni A et al.
Oncotarget, 2021
KEAP1/NFE2L2 Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase Inhibition.
Binkley MS et al.
Cancer Discovery, 2020
NRF2-Driven KEAP1 Transcription in Human Lung Cancer.
Tian Y et al.
Molecular Cancer Research : Mcr, 2020
Loss-of-function mutations in KEAP1 drive lung cancer progression via KEAP1/NRF2 pathway activation.
Gong M et al.
Cell Communication and Signaling : Ccs, 2020
Impacts of NRF2 activation in non-small-cell lung cancer cell lines on extracellular metabolites.
Saigusa D et al.
Cancer Science, 2020
ERBB3 and IGF1R Signaling Are Required for Nrf2-Dependent Growth in KEAP1-Mutant Lung Cancer.
Vartanian S et al.
Cancer Research, 2019
Oncogenic PIK3CA mutations increase dependency on the mRNA cap methyltransferase, RNMT, in breast cancer cells.
Dunn S et al.
Open Biology, 2019
Aldo-keto reductases are biomarkers of NRF2 activity and are co-ordinately overexpressed in non-small cell lung cancer.
MacLeod AK et al.
British Journal of Cancer, 2016
Modification of platinum sensitivity by KEAP1/NRF2 signals in non-small cell lung cancer.
Tian Y et al.
Journal of Hematology & Oncology, 2016
Molecular mechanisms of the Keap1–Nrf2 pathway in stress response and cancer evolution.
Taguchi K et al.
Genes to Cells : Devoted to Molecular & Cellular Mechanisms, 2011